Using the method, the researchers predicted the effects of over 140 million mutations in different tissues and identified mutations possibly associated with increased risk of several immune diseases.
Research presented at the Intelligent Systems for Molecular Biology conference shows promise in uncovering more SNP-phenotype links in GWAS.
The company said it plans to use the technology to derive clinical insights from the large-scale proteomic datasets generated by its SomaScan platform.
Silicon Valley VC firm DFJ led the investment in Verge, which is applying machine learning to the development of new drugs for Parkinson's and ALS.
NewStem is developing a technology that uses human haploid embryonic stem cells to predict cancer drug resistance.
The company has two clinical utility studies underway and one large clinical validity study slated for publication later this year.
Organizers of a data analysis challenge remain hopeful that a recent update to the Connectivity Map resource will lead to breakthroughs in DILI detection by next year.
NuMedii will use its AI technology in combination with single-cell data to identify biomarkers and therapeutics for idiopathic pulmonary fibrosis.
The companies will combine their respective services into a single end-to-end offering for microbiome research.
DeCode's new offering adds to an ongoing controversy over whether people in the island country have a right to know if they are at increased risk for disease.
The technique features sequencing-by-ligation and error-correction strategies, and was used to simultaneously map more than 1,000 genes in mouse brain tissue.
As Dana-Farber migrates its dozens of medical and radiation oncology protocols to the Philips platform, its focus is on digital pathology, genomics, and informatics.
The grant will support the consortium's ongoing efforts to clinically validate data analysis software for monitoring treatment responses to cancer vaccines.
The approach, published this week in Cell Reports, could be used more generally to discover disease genes in other cancer types.
The partners are aiming to generate proteomic and phosphoproteomic data that they can include in Indivumed's global cancer database.
Finland-based Tieto and Swiss firm BC Platforms will jointly develop technology for integrating genomic and clinical data in the Northern European market.
Researchers at Columbia University and CHOP believe they can shorten time to diagnosis and improve yield by extracting phenotypic data from EHRs for genomic labs.
The partners have been working together since 2013 to use cancer and cardiovascular genomics for drug discovery.
Through the deal, Precision Therapeutics will acquire the 75 percent stake in Helomics that it does not already own.
The partners have established a laboratory to investigate cell-free DNA and other bloodborne molecules as cancer biomarkers.
In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.
At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.
The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.
Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.